Thursday, 27 January 2022
  
Login

Australia's most trusted
source of pharma news

Thursday, 27 January 2022
News

Patent loss bites BMS hard

Posted 1 December 2021 AM

BMS is set to lose around $15 million from the value of leukemia drug Sprycel thanks to a 25 per cent price cut as it moves from F1 to F2 on the PBS today (Wednesday).

The patent expiry that brought on the cut also opens the way to competition that will further devalue the drug for its originating sponsor.

To see the whole article, please login

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.